SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending as discussions erupt over former President Trump's threats of new tariffs on European nations, stemming from their stance on Greenland and his apparent frustrations regarding the Nobel Peace Prize. This has ignited heated debate among the community, with many expressing concern over potential market instability and strained international relations, while supporters view these actions as beneficial for "America First" economic policies.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as a significant validation of its platform technology across potential new disease areas. The community is actively discussing the potential for upfront payments, substantial milestones, and royalties, while also looking for further partnerships, particularly for its advanced COVID-Flu combination vaccine. This recent strategic move, alongside the company's strengthened financial position, is generating optimism about future growth despite ongoing activist investor pressure.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is currently trending due to news of a strategic acquisition and a recent public offering that sparked extreme volatility. The community is sharply divided between anticipating massive upside driven by its low float and projected profitability, and expressing caution over its significant price swings. Traders are actively debating if this presents a compelling buying opportunity or a cautionary tale, drawing parallels to other high-momentum low-float stocks.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing heightened volatility as President Trump's escalating tariff threats against NATO allies, particularly concerning Greenland, spark widespread geopolitical uncertainty. Community sentiment is sharply divided, with some anticipating a deeper market correction while others view the current downturn as a 'buy the dip' opportunity amidst global bond market concerns and a notable rise in precious metal prices. Investors are closely monitoring a potential Supreme Court ruling on tariffs as a key market mover.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma TransCode Therapeutics Announces Publication of Preclinical Data...

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors...

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial TransCode...

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot...

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO TransCode Therapeutics presents preliminary data from its completed...

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html">announced</a> a $25 million investment from CK Life Sciences, expected to be used to advance the clinical development of its lead microRNA asset called TTX-MC138 into a mid-stage clinical trial. The candidate is believed to be a master regulator of metastatic cancer across multiple indications.Shares of the company soared 55% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNAZ">RNAZ stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Polynoma is developing a late-stage candidate called seviprotimut-L, a vaccine aimed at melanoma patients who have limited options in stage IIB and IIC.“Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," TransCode’s new CEO, Philippe Calais, said.TransCode on Wednesday also announced that Calais has been appointed as the company CEO while remaining Chairman of the Board of Directors. Tom Fitzgerald stepped down as Interim CEO but remains CFO, it added.While there are no other changes to TransCode’s executive team, the company expects to retain several finance, development, and manufacturing professionals from Polynoma, it added.RNAZ stock is down by 87% this year and by 97% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stifel-hikes-price-target-on-tesla-after-fsd-v14-roll-out/ch6EKRbR3i9">Stifel Hikes Price Target On Tesla After FSD V14 Roll Out, Reiterates Hopes In Robotaxi</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 

Equity

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 


Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its Phase 1a clinical trial of TTX-MC138, an experimental therapy targeting metastatic cancer.TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b (miR-10b), a genetic target believed to play a critical role in the emergence and progression of several metastatic cancers.&nbsp;According to TransCode, 13 patients have been treated with TTX-MC138 across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.&nbsp;Eight patients remain on study, receiving additional doses during each 28-day treatment cycle, and two patients have been on therapy for approximately seven months with stable disease observed.No dose-limiting toxicities or significant safety concerns have been reported in the trial. Preliminary pharmacokinetic and pharmacodynamic data also align with earlier preclinical and Phase 0 findings.&nbsp;The results support advancing to the planned Phase 1b dose expansion, where researchers will further evaluate safety and early anti-tumor signals.The company’s financial position has been a key focus. As of April 2025, TransCode reported a cash balance of $5.81 million, with total liabilities exceeding assets by $2.02 million.&nbsp;Recent fundraising has helped shore up liquidity, including a $10.05 million registered direct offering in March 2025 and a $7.19 million equity raise in January.&nbsp;Last week, H.C. Wainwright lowered its price target on TransCode to $10 from $20 while maintaining a ‘Buy’ rating, according to The Fly.The firm cited recent equity raises as the reason for the revision but noted that its updated model assumes current funds are sufficient to support operations into 2026.Retail enthusiasm was evident on Stocktwits as sentiment was described as ‘extremely bullish,’ with message volume reaching ‘extremely high’ levels.&nbsp;Traders speculated on further upside, with some suggesting the stock could soon surpass the $1 mark and noting bullish chart patterns that could support another leg higher in after-hours trading.<stembedurl>https://stocktwits.com/ProfessorDman1/message/613317226</stembedurl><stembedurl>https://stocktwits.com/al_fred/message/613270466</stembedurl>Despite Thursday’s sharp rebound, TransCode shares remain down 84% year-to-date, far underperforming the broader market.&nbsp;By comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An electronic board displays information on recent fluctuations of market indices at the B3 Stock Exchange in Sao Paulo, Brazil, on April 7, 2025. (Photo by Cris Faga/NurPhoto via Getty Images)

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns. 

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Current Price	$8.35
Prev Close	$8.94
Open	$8.90
Dividend Yield	0.00%
50-Day Moving Average	$8.48
Beta	1.92
Avg. Volume	26,058.82
PE Ratio	-0.04

52-Week High	$468.44
52-Week Low	$6.08
Market Capitalization	$8.2M
EPS (Annual)	-$1,317.38
Price to Book	5.23
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RNAZ
TransCode Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest RNAZ News

RNAZTransCode Therapeutics Inc